Targeting V1A-vasopressin receptors with [Arg6, D-Trp7,9, NmePhe8]-substance P (6-11) identifies a strategy to develop novel anti-cancer therapies

Alison C. Mackinnon, Uzma Tufail-hanif, Mark Wheatley, Adriano G. Rossi, Christopher Haslett, Michael Seckl, Tariq Sethi

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)36-47
JournalBritish Journal of Pharmacology
Issue number1
Publication statusPublished - 1 Jan 2009

Cite this